Replies to post #718900 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Shallup,

I don’t think they’re similar. Only the SP looks similar, but APTO has a market cap of 6.5 million which is very different from the mkt cap of NWBO.

I haven’t really looked at APTO, but I don’t think the company is comparable to NWBO. They’re developing some kind of technology aimed at blood cancers.

NWBO has a cell-based platform technology that was studied mostly for the treatment of nGBM and rGBM, but the technology may be applicable to other solid tumor cancers too.

NWBO has clinical data that were independently peer reviewed and published, and the company is awaiting completion of MHRA review of their commercial marketing application. The company is working to solidify scalable manufacturing capacity, forthcoming additional regulatory filings, and their technology is being studied in ongoing combo trials.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175048830